Regulatory approval

Published by the Health Service Executive. Withdrawn

Treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC) as monotherapy after failure of fluoropyrimidine, oxaliplatin, and irinotecan containing chemotherapy regimens.

This is written in the approval document.

Reimbursement

N/A

Citation

Panitumumab 6mg/kg Therapy, 2026, version number 6, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6560/225_Panitumumab_6mgkg.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2014-04-05	Health Service Executive	Indication approved for reimbursement.